Evidence map›Paper›PMID 35743495›Full record

ArticleJournal of clinical medicine2022

Impact of Continuous Flow Left Ventricular Assist Device on Heart Transplant Candidates: A Multi-State Survival Analysis.

Massimiliano Carrozzini, Tomaso Bottio, Raphael Caraffa, Jonida Bejko, Olimpia Bifulco, Alvise Guariento, Carlo Mario Lombardi, Marco Metra, Danila Azzolina, Dario Gregori and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 3 countries.

Massimiliano CarrozziniDepartment of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.ORCID 0000-0001-5506-0201
Tomaso BottioDepartment of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.ORCID 0000-0001-7299-2983
Raphael CaraffaDepartment of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.ORCID 0000-0001-9651-3473
Jonida BejkoDepartment of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.
Olimpia BifulcoDepartment of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.
Alvise GuarientoDepartment of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.
Carlo Mario LombardiCardiothoracic Unit, Spedali Civili of Brescia, Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University, 25121 Brescia, Italy.
Marco MetraCardiothoracic Unit, Spedali Civili of Brescia, Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University, 25121 Brescia, Italy.
Danila AzzolinaDepartment of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.
Dario GregoriDepartment of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.ORCID 0000-0001-7906-0580
Marny FedrigoDepartment of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.
Chiara CastellaniDepartment of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.ORCID 0000-0002-0275-4864
Vincenzo TarziaDepartment of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.
Giuseppe ToscanoDepartment of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.
Antonio GambinoDepartment of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.
Vjola JorgjiHacohen Lab, Massachusetts General Hospital, Boston, MA 02114, USA.
Enrico FerrariCardiac Surgery Unit, Cardiocentro Ticino Institute, 6900 Lugano, Switzerland.ORCID 0000-0002-2837-3242
Annalisa AngeliniDepartment of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.ORCID 0000-0002-3578-4488
Gino GerosaDepartment of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.ORCID 0000-0002-6261-699X
University of Padua · ITUniversity of Brescia · ITMassachusetts General Hospital · USUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Objectives: The aim of this study was to investigate the impact of the prolonged use of continuous-flow left ventricular assist devices (LVADs) on heart transplant (HTx) candidates. (2) Methods: Between January 2012 and December 2019, we included all consecutive patients diagnosed with end-stage heart failure considered for HTx at our institution, who were also eligible for LVAD therapy as a bridge to transplant (BTT). Patients were divided into two groups: those who received an LVAD as BTT (LVAD group) and those who were listed without durable support (No-LVAD group). (3) Results: A total of 250 patients were analyzed. Of these, 70 patients (28%) were directly implanted with an LVAD as BTT, 11 (4.4%) received delayed LVAD implantation, and 169 (67%) were never assisted with an implantable device. The mean follow-up time was 36 ± 29 months. In the multivariate analysis of survival before HTx, LVAD implantation showed a protective effect: LVAD vs. No-LVAD HR 0.01 (p < 0.01) and LVAD vs. LVAD delayed HR 0.13 (p = 0.02). Mortality and adverse events after HTx were similar between LVAD and No-LVAD (p = 0.65 and p = 0.39, respectively). The multi-state survival analysis showed a significantly higher probability of death for No-LVAD vs. LVAD patients with (p = 0.03) or without (p = 0.04) HTx. (4) Conclusions: The use of LVAD as a bridge to transplant was associated with an overall survival benefit, compared to patients listed without LVAD support.

Indexed as

bridge to transplant strategyleft ventricle assist devicemechanical circulatory support heart transplantmulti-state survival analysiswaitlist survival

Identifiers

PMID35743495
PMCPMC9225476
OpenAlexW4282920419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.